



Teiko.bio

Precision Immune Monitoring


What **looking beyond the tumor
microenvironment** taught us about
immunotherapy




How does immunotherapy work?

Immunotherapy ...


... reinvigorates exhausted T cells in the tumor microenvironment



... brings new, non-exhausted T cells to the tumor microenvironment



Spitzer et al. showed that peripheral immune cells are required for immunotherapy in mouse models



Other studies have replicated these findings in different mouse models


Human studies confirmed immunotherapy induces tumor infiltration by fresh peripheral T cell clones

Tumor-resident T cell clones are present in blood before immunotherapy



Tumor infiltration by fresh peripheral CD8 T cell clones

Immunotherapy controls tumors by improving tumor infiltration by fresh clones from the blood



Several labs showed that these fresh T cells are activated in lymph nodes before entering the blood




[Schenkel et al. Immunity 2021](#)

Immunity

[Connolly et al. Sci Immunol 2021](#)

Science Immunology




[Rahim, Okholm, Jones et al. Cell 2023](#)

Cell


How does immunotherapy work?

Immunotherapy ...

... reinvigorates
exhausted T cells in the
tumor microenvironment



... brings new, non-exhausted
T cells to the tumor
microenvironment





Peripheral T cells are associated with better clinical outcomes in humans

Clinical response / OS associated with:

After one cycle of immunotherapy

- Peripheral T cell clonal turnover
- Frequency of peripheral CD8 TEM cells
- Expression of cytotoxic / effector genes in peripheral CD8 T cell clones




Baseline **blood** can stratify response to anti-PD-1 checkpoint inhibitor therapy


Non-Small Cell Lung Cancer

CANCER IMMUNOLOGY
RESEARCH

[Kagamu, et. al.](#)
[2020](#)



+45%
Progression Free
Survival



+ 50%
Overall
Survival

↑ CD62L^{low} in total populations of
CD4⁺, CD8⁺ T cells

↑ CD25⁺FOXP3⁺ CD4⁺ T cells
[P = 0.034]

Sensitivity of 92.9%, specificity of 72.1%
n=40 patient prediction cohort
n=86 patient validation cohort

Teiko has shown that baseline levels of peripheral T cells are associated with adverse events (irAE)

n=29 patients
with
metastatic
melanoma



**Want to learn more?
Teiko.bio**
